AdvisorNet Financial Inc Sells 827 Shares of Novo Nordisk A/S (NYSE:NVO)

AdvisorNet Financial Inc trimmed its stake in Novo Nordisk A/S (NYSE:NVOGet Rating) by 49.3% during the 2nd quarter, Holdings Channel reports. The firm owned 852 shares of the company’s stock after selling 827 shares during the quarter. AdvisorNet Financial Inc’s holdings in Novo Nordisk A/S were worth $95,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. MML Investors Services LLC grew its position in Novo Nordisk A/S by 6.2% during the fourth quarter. MML Investors Services LLC now owns 42,938 shares of the company’s stock valued at $4,809,000 after acquiring an additional 2,509 shares during the last quarter. American Century Companies Inc. grew its position in Novo Nordisk A/S by 15.4% during the first quarter. American Century Companies Inc. now owns 110,941 shares of the company’s stock valued at $12,320,000 after acquiring an additional 14,816 shares during the last quarter. Westwood Holdings Group Inc. grew its position in Novo Nordisk A/S by 75.8% during the fourth quarter. Westwood Holdings Group Inc. now owns 13,282 shares of the company’s stock valued at $1,487,000 after acquiring an additional 5,726 shares during the last quarter. Cetera Advisor Networks LLC grew its position in Novo Nordisk A/S by 22.8% during the first quarter. Cetera Advisor Networks LLC now owns 20,220 shares of the company’s stock valued at $2,245,000 after acquiring an additional 3,753 shares during the last quarter. Finally, Ipswich Investment Management Co. Inc. grew its position in Novo Nordisk A/S by 1.4% during the first quarter. Ipswich Investment Management Co. Inc. now owns 52,380 shares of the company’s stock valued at $5,817,000 after acquiring an additional 710 shares during the last quarter. 6.62% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $99.22 on Thursday. The company has a current ratio of 0.94, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $224.53 billion, a P/E ratio of 29.62, a P/E/G ratio of 1.80 and a beta of 0.47. The business has a fifty day simple moving average of $107.83 and a two-hundred day simple moving average of $109.30. Novo Nordisk A/S has a 12 month low of $91.51 and a 12 month high of $122.16.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 23rd. Shareholders of record on Monday, August 15th were given a dividend of $0.5836 per share. This represents a yield of 1.1%. The ex-dividend date of this dividend was Friday, August 12th. Novo Nordisk A/S’s dividend payout ratio is currently 24.18%.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Morgan Stanley raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, July 15th. JPMorgan Chase & Co. raised Novo Nordisk A/S from a “neutral” rating to an “overweight” rating in a research note on Tuesday, June 7th. Exane BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a 750.00 price objective for the company in a research note on Monday, June 27th. UBS Group lowered Novo Nordisk A/S from a “neutral” rating to a “sell” rating in a research note on Tuesday, June 28th. Finally, BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $750.00 price objective for the company in a research note on Monday, June 27th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $682.43.

About Novo Nordisk A/S

(Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Featured Articles

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOGet Rating).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.